Drug Trial Radar · NCT07128615
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
405
Actual
Start
Sep 4, 2025
Primary completion
Jan 28, 2026
Study completion Dec 29, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority; Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
Conditions
- Influenza A
Interventions
AZD4117Biological
Intramuscular (IM) injection
AZD5315Biological
IM injection
PlaceboOther
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with immediate unsolicited adverse events (AE)Time frame: Within 30 minutes after dosing
- Percentage of participants with injection site and systemic solicited adverse reactions (AR)Time frame: Through 7 days after dosing
- Percentage of participants with unsolicited AETime frame: Through 28 days after the last dose
- Percentage of participants with serious adverse events (SAE)Time frame: Through 12 months after the last dose
- Percentage of participants with medically attended adverse events (MAAE)Time frame: Through 12 months after the last dose
- Percentage of participants with adverse events of special interest (AESI)Time frame: Through 12 months after the last dose
- Proportion of participants achieving ≥ 1:40 HAI titer post-IMP administrationTime frame: Day 58
- Proportion of participants achieving seroconversion post-IMP administrationTime frame: Day 58
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Long Beach, California
Research Site
Rolling Hills Estates, California
Research Site
Miami Lakes, Florida
Research Site
Stockbridge, Georgia
Research Site
Chicago, Illinois
Research Site
Lenexa, Kansas
Research Site
Kansas City, Missouri
Research Site
Omaha, Nebraska
Research Site
Las Vegas, Nevada
Research Site
Cincinnati, Ohio
Research Site
Edmond, Oklahoma
Research Site
North Charleston, South Carolina
Research Site
Austin, Texas
Research Site
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.